CCR2 and metabolic dysfunction-associated steatohepatitis: UC-MSC treatment is safe and does not increase the occurrence of HCC events, and it has a long-term effect on improving liver function and survival in patients with decompensated liver cirrhosis.548 In addition, CCR2 overexpression in MSCs improves the treatment effect of MSCs by enhancing the targeted migration of stem cells to damaged livers,533 and may provide a novel strategy for improving the efficacy of cell therapy for NASH.